Trial Profile
A Pilot Trial of Ipilimumab With Nivolumab for Participants With Resected Stages IIIB/IIIC/ IV Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 11 Aug 2022 Status changed from active, no longer recruiting to completed.
- 18 Jan 2022 Planned End Date changed from 1 Apr 2021 to 1 Feb 2022.
- 04 Feb 2021 Planned End Date changed from 1 Nov 2020 to 1 Apr 2021.